Navigation Links
Animal study suggests that newborn period may be crucial time to prevent later diabetes

Pediatric researchers who tested newborn animals with an existing human drug used in adults with diabetes report that this drug, when given very early in life, prevents diabetes from developing in adult animals. If this finding can be repeated in humans, it may become a way to prevent at-risk infants from developing type 2 diabetes.

"We uncovered a novel mechanism to prevent the later development of diabetes in this animal study," said senior author Rebecca A. Simmons, M.D., a neonatologist at The Children's Hospital of Philadelphia. "This may indicate that there is an important developmental window, a period of time in which we can intervene to permanently protect the body's insulin-producing cells."

Simmons and lead author Sara E. Pinney, M.D., a pediatric endocrinologist at Children's Hospital, published the study in the October issue of Diabetologia.

The research may be relevant to children with intrauterine growth retardation (IUGR), a common complication during the mother's pregnancy. Simmons' previous research showed that IUGR, which is associated with decreased availability of nutrients and hormones to the developing fetus, permanently alters gene expression and impairs the function of insulin-producing cells in the pancreas. These defects have been shown to cause type 2 diabetes to develop in adulthood.

The study team used exendin-4 (Ex-4), a drug recently approved for use in adults with type 2 diabetesa condition in which a patient produces insufficient insulin, or is unable to process insulin normally. Although the drug's mechanism is not known, it has a hormone-like effect, raising insulin secretion in adults.

In their study, Simmons and Pinney used rats with an induced form of IUGR. They found that after being given to newborn rats, Ex-4 had epigenetic effectsmodifying gene function without changing the underlying DNA sequences. Ex-4 increased the expression of a gene called Pdx1 that is necessary for beta cells to function properly. Beta cells produce insulin in the pancreas of mammals, including humans.

"In our study, giving exendin-4 during the newborn period had permanent beneficial effects on beta cells," said Pinney. "This could be important for people, in whom abnormal changes in infancy may irreversibly alter beta cells and lead to adult-onset diabetes. If we can establish that treating at-risk human babies with exendin-4 or a similar compound has corresponding effects, we may have a new preventive approach for type 2 diabetes."

Simmons and Pinney cautioned that much follow-up research remains to be done, such as investigating more of the basic biology and evaluating the genome-wide effects of exendin-4, before their research findings could translate into clinical use in children.


Contact: John Ascenzi
Children's Hospital of Philadelphia

Related biology news :

1. Long-term study shows effect of climate change on animal diversity
2. Researchers find animal with ability to survive climate change
3. Researchers note differences between people and animals on calorie restriction
4. Earliest animal footprints ever found -- discovered in Nevada
5. Details of evolutionary transition from fish to land animals revealed
6. Drug-embedded microparticles bolster heart function in animal studies
7. Swamping bad cells with good in ALS animal models helps sustain breathing
8. Moderate use averts failure of type 2 diabetes drugs in animal model
9. Grapes may aid a bunch of heart risk factors, animal study finds
10. Animal and biological science highlights: San Antonio Fluid Dynamics Conference, Nov. 23-25
11. Discovery of giant roaming deep sea protist provides new perspective on animal evolution
Post Your Comments:
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
Breaking Biology Technology: